Blood brain barrier state of a disease the chronic obstructive pulmonary disease-Central side effect measures of the inhalational anti-cholinergic drugs

慢性阻塞性肺疾病的血脑屏障状态-吸入性抗胆碱能药物的中枢副作用测定

• 批准号: 22790177
• 负责人: TOMINAGA Koji
• 金额: $ 2.58万
• 依托单位: Fukuoka University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (B)
• 财政年份: 2010
• 资助国家: 日本
• 起止时间: 2010 至 2011
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22790177/
• 关键词: 医療薬剤学; COPD; BBB; 中枢性副作用; 炎症; 血液脳関門; ペリサイト; 医療薬剤学; COPD; BBB; 中枢性副作用; 炎症; 血液脳関門; ペリサイト

We examined a change of the blood-brain barrier(BBB) function and the central nerve transition of the anticholinergic drugs in the chronic obstructive pulmonary disease(COPD). As result, in COPD model mouse, tight junction function of the BBB was decreased, and there is possibility that the intracerebral transmissiveness of the anticholinergic drug were aggravated. Therefore, in COPD, the brain internal transmigration of drugs are accelerated by BBB disfunction, and it was thought that expression of the central side effects such as cognitive function disorders are easy.

我们检查了慢性阻塞性肺疾病（COPD）中抗胆碱能药物（COPD）的血脑屏障（BBB）功能的变化和中心神经转变。结果，在COPD模型小鼠中，BBB的紧密连接函数降低，并且可能会加重抗胆碱能药物的脑内透射率。因此，在COPD中，药物的大脑内部迁移是通过BBB功能加速的，人们认为中心副作用（例如认知功能障碍）的表达很容易。